LEGNStockLegend Biotech Corp - ADR
Verdicts genuinely change. Free email alert the moment LEGN's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Legend Biotech Corp - ADR (LEGN) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 449 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2025-12-31. LEGN files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.75% | 30.00% | Pass |
| Interest-bearing investments | 24.73% | 30.00% | Pass |
| Non-permissible income | 0.00% | 5.00% | Pass |
Usmani Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.41% | 33.00% | Pass |
| Interest-bearing investments | 52.02% | 33.00% | Fail |
| Non-liquid assets | 47.98% | at least 20.00% | Pass |
| Non-permissible income | 0.00% | 5.00% | Pass |
MSCI Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.41% | 33.33% | Pass |
| Cash + interest-bearing securities | 52.02% | 33.33% | Fail |
| Non-permissible income | 0.00% | 5.00% | Pass |
FTSE Fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.41% | 33.33% | Pass |
| Cash + interest-bearing securities | 52.02% | 33.33% | Fail |
| Non-permissible income | 0.00% | 5.00% | Pass |
Dow Jones Islamic Market Unverified⚠️ a figure this standard divides by was not available — the ratios shown were computed, this standard needs one more that was not
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.36% | 33.00% | Pass |
| Cash + interest-bearing securities | 15.15% | 33.00% | Pass |
| Non-permissible income | 0.00% | 5.00% | Pass |
S&P Shariah Unverified⚠️ a figure this standard divides by was not available — the ratios shown were computed, this standard needs one more that was not
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.25% | 33.00% | Pass |
| Cash + interest-bearing securities | 12.01% | 49.00% | Pass |
| Non-permissible income | 0.00% | 5.00% | Pass |
MSCI M-Series Unverified⚠️ a figure this standard divides by was not available — the ratios shown were computed, this standard needs one more that was not
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.25% | 33.33% | Pass |
| Cash + interest-bearing securities | 12.01% | 33.33% | Pass |
| Non-permissible income | 0.00% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from LEGN's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $1.0B | 2025-12-31 | RevenueFromContractsWithCustomers |
| Interest-bearing debtShort and long-term borrowings | $319.1M | 2025-12-31 | Borrowings |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $901.9M | 2025-12-31 | CashAndCashEquivalents |
| Total assetsBalance sheet total | $1.7B | 2025-12-31 | Assets |
| Market capDenominator for AAOIFI | $3.6B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $14.1B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $11.2B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2025-12-31 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
What changed, and when
Verdict history for LEGN. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for LEGN has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.10 | NEUTRAL |
| Stochastic %K (14) | 16.07 | BUY |
| CCI (20) | -50.58 | NEUTRAL |
| Williams %R (14) | -83.93 | BUY |
| MACD (12,26,9) | 0.07 | BUY |
| ROC (10) | -1.99 | SELL |
| Momentum (10) | -0.37 | SELL |
| EMA (10) | 18.72 | SELL |
| SMA (10) | 18.88 | SELL |
| EMA (20) | 18.93 | SELL |
| SMA (20) | 18.55 | SELL |
| EMA (30) | 19.27 | SELL |
| SMA (30) | 19.16 | SELL |
| EMA (50) | 20.13 | SELL |
| SMA (50) | 19.75 | SELL |
| EMA (100) | 21.75 | SELL |
| SMA (100) | 23.85 | SELL |
| EMA (200) | 22.62 | SELL |
| SMA (200) | 22.31 | SELL |
About Legend Biotech Corp - ADR
Healthcare · Biotechnology
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-08-18
Stop 20.97 Now 18.20 Target 22.53
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 64 |
| ⏰ 4H | RANGING | 39 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
BEARISH 0 buys · 1 sells
Recent: Casey Patrick John sold 48604 sh @ $14.80 (2026-06-30)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-06 · Asset managers net 906615 (+2612)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.